# Dr Agarwals Eye Hospital (NSE: DRAGARWQ) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DRAGARWQ · Pivot · prices to 22 Oct 2026

Dr Agarwals Eye Hospital (NSE: DRAGARWQ) closed at ₹5,025.00 on 22 Oct 2026, up 0.12% on the day. With a market capitalisation of ₹2,428 Cr, it ranks 1055th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.

Its return on equity was 26.1% in FY25. Its 52-week range is ₹4,600.00 (21 Apr 2026) to ₹6,059.70 (21 May 2026); the last close is 17.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹143 Cr (+22.3% year on year) and net profit ₹23 Cr (+35.5%), on a standalone basis. Promoters held 72.67% of the company as of 30 Jun 2026; 7.67% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹5,025.00 |
| Market cap | ₹2,428 Cr |
| ROE | 26.1% (FY25) |
| ROCE | 16.0% (FY25) |
| Debt to equity | 0.46 |
| 52-week high | ₹6,059.70 (21 May 2026) |
| 52-week low | ₹4,600.00 (21 Apr 2026) |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹143 Cr | +22.3% | ₹23 Cr | +35.5% | ₹48.38 |
| Q4 FY26 | ₹120 Cr | +20.2% | ₹16 Cr | +1.6% | ₹33.60 |
| Q3 FY26 | ₹116 Cr | +22.2% | ₹17 Cr | +66.2% | ₹35.76 |
| Q2 FY26 | ₹118 Cr | +15.2% | ₹19 Cr | +36.5% | ₹41.04 |
| Q1 FY26 | ₹117 Cr | +16.9% | ₹17 Cr | +22.3% | ₹36.72 |
| Q4 FY25 | ₹100 Cr | +23.7% | ₹16 Cr | +25.0% | ₹34.02 |
| Q3 FY25 | ₹95 Cr | +25.7% | ₹10 Cr | +10.2% | ₹22.13 |
| Q2 FY25 | ₹102 Cr | +22.7% | ₹14 Cr | +12.4% | ₹30.11 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹397 Cr | ₹55 Cr |
| FY24 | ₹319 Cr | ₹46 Cr |
| FY23 | ₹268 Cr | ₹37 Cr |
| FY22 | ₹201 Cr | ₹24 Cr |
| FY21 | ₹140 Cr | −₹1 Cr |
| FY20 | ₹176 Cr | ₹14 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.67%
- Foreign institutions: 2.24%
- Domestic institutions: 2.05%
- Non-institutions: 23.04%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |
| [Hikal](https://app.pivotnow.in/stock/HIKAL) | ₹210.01 | ₹2,589 Cr | — | — |
| [Venus Remedies](https://app.pivotnow.in/stock/VENUSREM) | ₹1,796.10 | ₹2,401 Cr | 23.3 | — |
| [Alembic](https://app.pivotnow.in/stock/ALEMBICLTD) | ₹92.33 | ₹2,371 Cr | 7.5 | — |
| [Fredun Pharmace](https://app.pivotnow.in/stock/FREDUN) | ₹1,376.10 | ₹2,276 Cr | 22.5 | — |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹141.95 | ₹2,226 Cr | 22.8 | — |

## Questions and answers

### What is the share price of Dr Agarwals Eye Hospital today?

Dr Agarwals Eye Hospital (NSE: DRAGARWQ) last closed at ₹5,025.00 on 22 Oct 2026. Its 52-week high is ₹6,059.70 and its 52-week low is ₹4,600.00.

### What is the market cap of Dr Agarwals Eye Hospital?

Dr Agarwals Eye Hospital's market capitalisation is ₹2,428 Cr (₹2,428 Cr) at the 22 Oct 2026 close, ranking 1055th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Dr Agarwals Eye Hospital?

Return on equity was 26.1% in FY25 and return on capital employed was 16.0% in FY25 (standalone figures).

### Is Dr Agarwals Eye Hospital a debt-free company?

No. Dr Agarwals Eye Hospital's debt-to-equity ratio was 0.46 in FY25, with total debt of ₹82 Cr.

### What were Dr Agarwals Eye Hospital's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Dr Agarwals Eye Hospital reported revenue of ₹143 Cr, +22.3% year on year, and net profit of ₹23 Cr, +35.5% year on year.

### What is the shareholding pattern of Dr Agarwals Eye Hospital?

As of 30 Jun 2026: promoters 72.67%, foreign institutions 2.24%, domestic institutions 2.05%, non-institutions 23.04%. 7.67% of promoter shares were pledged.

### Who are Dr Agarwals Eye Hospital's competitors?

The listed Pharma & Healthcare companies closest to Dr Agarwals Eye Hospital by market cap are Dishman Pharma, Hikal, Venus Remedies, Alembic, Fredun Pharmace and Dishman Carbogen Amcis.

### Is Dr Agarwals Eye Hospital a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Dr Agarwals Eye Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DRAGARWQ against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.